October 01, 2016 5:35 PM ET


Company Overview of HUYA Bioscience International, LLC

Company Overview

HUYA Bioscience International, LLC engages in identifying and licensing pre-clinical and clinical stage compounds in China. It engages in accelerating the development of biopharmaceutical product opportunities originating in China. The company offers HBI-8000, a histone deacetylases inhibitors for cancer; HBI-3000, a multi-ion channel blocker for the treatment of arrhythmia; and HBI-3802, a small molecule for improving heart function, as well as stimulates cardiac stem cell differentiation into functional cardiomyocytes, and replaces and remodels dead myocardium with new functional tissues. The company has strategic alliances with China Wuqing Development Area and Korea Drug Development Fund...

12531 High Bluff Drive

Suite 138

San Diego, CA 92130

United States

Founded in 2004





Key Executives for HUYA Bioscience International, LLC

Founder and Executive Chairman
Age: 52
Chief Technology Officer and Chief Operating Officer of Asia
Chief Scientific Officer and Executive Vice President
Age: 56
Head of Therapeutics China
Chief Business Officer
Age: 65
Compensation as of Fiscal Year 2016.

HUYA Bioscience International, LLC Key Developments

Huya Presents at ChinaBio Partnering Forum 2016, May-19-2016 03:30 PM

Huya Presents at ChinaBio Partnering Forum 2016, May-19-2016 03:30 PM. Venue: Suzhou, China.

HUYA Bioscience International Announces the Appointment of John Ratliff as President and CEO

HUYA Bioscience International, announced the appointment of John Ratliff as President and CEO. This appointment is part of the company's long term growth plan. Dr. Mireille Gillings, who founded the company, continues as Executive Chair of its Board of Directors. John Ratliff brings over 30 years of experience in the biopharmaceutical and information technology industries.

HUYA Bioscience International (China) Enters into Licensing Agreement with Fudan University

HUYA Bioscience International (China) has signed an exclusive licensing agreement with China's Fudan University for rights in China to several novel immuno-oncology candidates. Under the agreement, HUYA plans to advance into clinical testing of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) developed by Fudan University scientists. In addition, HUYA also aims to proceed with ongoing development of its own novel histone deacetylase (HDAC) inhibitor HBI-8000. Financial details were not disclosed. The agreement will expand HUYA's immuno-oncology platform and potentially allow for the combination of other treatments. Huya has already entered into a licensing and development agreement with Eisai (Japan) for HBI-8000 in several Asian countries, potentially affording rapid market exposure for combination therapies. The partnership with Fudan University is also expected to leverage HUYA's experience in navigating market access.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HUYA Bioscience International, LLC, please visit www.huyabio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.